Who is sponsoring NCT02556411?

NCT02556411 is sponsored by University of Cagliari.

What condition does NCT02556411 study?

NCT02556411 studies Adenomyosis, Chronic Pelvic Pain.

What drugs are being tested in NCT02556411?

Interventions: LNG-IUS 13,5 mg Levonorgestrel, Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg.

What is the status of NCT02556411?

NCT02556411 is currently UNKNOWN.

Last reviewed 2021-02-04 · How we verify

Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02556411 NA UNKNOWN

Adenomyosis is characterized by the appearance of endometrial cells in the muscular layer of the uterus. It affects about 15-20% of the female population. The symptoms of adenomyosis are heavy menstrual bleedings and painful menstruation (dysmenorrhea) and in addition chronic pelvic pain. Regarding treatment levonogestrel-releasing intrauterine system, Gonadotropin releasing hormone (GnRH)-analogues, Danazol, uterine embolization and endometrial ablation have been tried. The aim of this study is to compare the efficacy and usefulness of association of oral contraceptive pill and LNG-IUS or LNG-IUS alone

Details

Lead sponsor	University of Cagliari
Phase	NA
Status	UNKNOWN
Enrolment	50
Start date	Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Adenomyosis
Chronic Pelvic Pain

Interventions

LNG-IUS 13,5 mg Levonorgestrel
Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg